News

Buy Cipla Ltd For Target Rs. 1,543 By Choice Broking Ltd Cipla Q2FY25 earnings were in line with our expectations on all fronts, with the reported revenue of INR 70,510mn (+5.6% YoY/+5.3% QoQ) driven by growth across all the focused geographies. EBITDA reported at INR 18,856mn (+8.8% YoY/+9.9% QoQ) with the highest ever quarterly margin of 26.7% (+78bps YoY and +111bps QoQ). Adj. PAT was reported at INR 13,025mn with a growth of 15.2% YoY and 10.6% QoQ. The management expects the launch of Advair by mid-FY26, while Abraxane’s release depends ...
Buy Cipla Ltd For Target Rs. 1,543 By Choice Broking Ltd
Buy Cipla Ltd For Target Rs. 1,543 By Choice Broking Ltd
Source: Choice Broking
2024-11-14 05:05:45 pm
Neutral Cipla Ltd For Target Rs.1,420 By Motilal Oswal Financial Services Ltd 2Q in-line; speed breaker ahead for growth in earnings * Cipla Ltd (CIPLA)’s 2QFY25 operational performance was in line with expectations. This was the fifth consecutive quarter of slowdown in YoY growth in revenue. The superior performance in SAGA/emerging market was offset by reduced YoY growth in domestic formulation (DF)/US. * We reduce our earnings estimate by 3%/4%/3% for FY25/FY26/FY27 to factor in: a) lower sales of Lanreotide on production modifications; b) unfa...
Neutral Cipla Ltd For Target Rs.1,420 By Motilal Oswal Financial Services Ltd
Neutral Cipla Ltd For Target Rs.1,420 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-11-13 10:49:07 am
Buy Cipla Ltd For Target Rs. 1,702 By Choice Broking Ltd * India Business: The India business reported revenues of INR 28,984mn (+4.6% YoY /19.9% QoQ). With respiratory expanding by 9%, cardiac by 11%, and urology growing by 15%, chronic therapies outperformed the market. The portfolio's overall chronic mix increased by 106bps to 61.5%. The transition of the India Trade Generics Business into a new distribution model will enable the company to enhance supply chain management. In the upcoming years, the management aims to outpace the IPM. The ma...
Buy Cipla Ltd For Target Rs. 1,702 By Choice Broking Ltd
Buy Cipla Ltd For Target Rs. 1,702 By Choice Broking Ltd
Source: Choice Broking Ltd
2024-09-02 05:11:44 pm
Buy Cipla Ltd For Target Rs.1,830 By Motilal Oswal Financial Services The US and emerging markets drive earnings Work in progress to address the issues highlighted in Goa 483 * Cipla delivered in-line 1QFY25 performance. It continued to track well in the US generics segment, with sales scaling an all-time quarterly high of USD250m. However, the benefit was partly offset by a temporary disruption in the trade generics segment. Cipla continues to outperform the industry in chronic therapies within the branded prescription segment. * We maintain our earnings...
Buy Cipla Ltd For Target Rs.1,830 By Motilal Oswal Financial Services
Buy Cipla Ltd For Target Rs.1,830 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd Ltd
2024-08-02 03:18:15 pm
Buy Cipla Ltd For Target Rs. 1,700 By Motilal Oswal Financial Services Classification of Goa inspection remains key Comprehensive measures required to resolve regulatory issues ? We assessed Form 483 issued by USFDA after inspection at Cipla’s Goa site. ? Form 483 highlights issues largely related to testing methods, monitoring environmental conditions, cleaning/disinfections and root cause analysis. ? Considering the observations, we await classification of the inspection to incorporate potential business from key products like g-Abraxane. ? Nonetheless, ...
Buy Cipla Ltd For Target Rs. 1,700 By Motilal Oswal Financial Services
Buy Cipla Ltd For Target Rs. 1,700 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
2024-07-11 04:30:59 pm
Orchid Pharma gains on partnering with Cipla to launch antibiotic Cefepime-Enmetazobactam in India Orchid Pharma is currently trading at Rs. 1150.35, up by 10.50 points or 0.92% from its previous closing of Rs. 1139.85 on the BSE. The scrip opened at Rs. 1161.75 and has touched a high and low of Rs. 1188.10 and Rs. 1140.40 respectively. So far 9237 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1358.80 on 26-Feb-2024 and a 52 week low of Rs. 432.35 on 26-Oct-2023. Last one week high and low of the scrip sto...
Orchid Pharma gains on partnering with Cipla to launch antibiotic Cefepime-Enmetazobactam in India
Orchid Pharma gains on partnering with Cipla to launch antibiotic Cefepime-Enmetazobactam in India
Source: Accord Fintech
2024-07-01 04:37:46 pm
Buy Cipla Ltd. For Target Rs. 1,600 - Motilal Oswal Financial Services The US/branded generics drive earnings Work in progress to build complex assets to sustain growth over 3-4 years * Cipla reported a slight miss on earnings for 4QFY24, largely due to higher opex. It ended FY24 on a strong note with 13%/23%/39% YoY growth in sales/EBITDA/PAT to INR257b/INR63b/INR42b. This was driven by strong traction in the US generics and superior execution in the branded generics segment within domestic formulations (DF) and South Africa. * We retain our earnings ...
Buy Cipla Ltd. For Target Rs. 1,600 - Motilal Oswal Financial Services
Buy Cipla Ltd. For Target Rs. 1,600 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
2024-06-23 02:38:21 pm
Stock of the day : Cipla Ltd. For Target Rs.1590 - Religare Broking Cipla Ltd  * Post the result outcome, defensive sectors are witnessing strong action and pharma is left no behind. * Among the space, CIPLA has recorded a fresh breakout from the consolidation range to the record high zone with strong surge in volume. * Considering, the price action and buoyancy in space, we expect bullish tone to continue. * Traders can consider fresh longs in the mentioned range. Buy Cipla Ltd CMP 1496.95 Range 1495...
Stock of the day : Cipla Ltd. For Target Rs.1590 - Religare Broking
Stock of the day : Cipla Ltd. For Target Rs.1590 - Religare Broking
Source: Religare Broking Ltd
2024-06-06 11:41:20 am
Cipla rises on getting USFDA’s final nod for Lanreotide injection Cipla is currently trading at Rs. 1457.80, up by 14.60 points or 1.01% from its previous closing of Rs. 1443.20 on the BSE. The scrip opened at Rs. 1451.10 and has touched a high and low of Rs. 1467.10 and Rs. 1437.10 respectively. So far 71397 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1519.00 on 11-Mar-2024 and a 52 week low of Rs. 915.50 on 22-May-2023. Last one week high and low of the scrip stood at Rs...
Cipla rises on getting USFDA’s final nod for Lanreotide injection
Cipla rises on getting USFDA’s final nod for Lanreotide injection
Source: Accord Fintech
2024-05-22 12:58:20 pm
Buy Cipla Ltd. For Target Rs.1,552 By Choice Broking Ltd Cipla Q4FY24 revenue was in line with the expectation, whereas earnings were above our estimates. The company reported a top line of INR 61,632mn (+7.4% YoY/-6.7% QoQ) which was driven by double-digit growth in the North American market and continued growth in India business. EBITDA reported at INR 13,159mn (+12.1% YoY/ -24.7% QoQ) and margin at 21.4% (+90bps YoY and -511bps QoQ). Adj. PAT was reported at INR 9,390mn with a robust growth of 43.7% YoY and a decline of 21.6% QoQ. The management...
Buy Cipla Ltd. For Target Rs.1,552 By Choice Broking Ltd
Buy Cipla Ltd. For Target Rs.1,552 By Choice Broking Ltd
Source: Choice Broking Ltd
2024-05-15 09:34:28 am
Cipla zooms on reporting 79% rise in Q4 consolidated net profit Cipla is currently trading at Rs. 1414.00, up by 74.55 points or 5.57% from its previous closing of Rs. 1339.45 on the BSE. The scrip opened at Rs. 1373.85 and has touched a high and low of Rs. 1425.65 and Rs. 1370.40 respectively. So far 91470 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1519.00 on 11-Mar-2024 and a 52 week low of Rs. 897.70 on 15-May-2023. Last one week high and low of the scrip stood at Rs...
Cipla zooms on reporting 79% rise in Q4 consolidated net profit
Cipla zooms on reporting 79% rise in Q4 consolidated net profit
Source: Accord Fintech
2024-05-13 11:23:32 am
India`s Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. 'Absolutely and always open...we value our partnership with Lilly tremendously and I think the two companies are culturally aligned," Cipla's Global CEO Umang Vohra said in response to a Reuters query. Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegov...
India`s Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
India`s Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Source: Reuters
2024-05-10 04:47:36 pm
Cipla gains as its arm acquires business undertaking from Ivia Beaute Cipla is currently trading at Rs. 1411.40, up by 3.85 points or 0.27% from its previous closing of Rs. 1407.55 on the BSE. The scrip opened at Rs. 1413.55 and has touched a high and low of Rs. 1416.25 and Rs. 1407.35 respectively. So far 8821 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1519.00 on 11-Mar-2024 and a 52 week low of Rs. 897.70 on 15-May-2023. Last one week high and low of the scrip stood at Rs. ...
Cipla gains as its arm acquires business undertaking from Ivia Beaute
Cipla gains as its arm acquires business undertaking from Ivia Beaute
Source: Accord Fintech
2024-04-30 03:34:29 pm
Sanofi India shines on entering into partnership with Cipla Sanofi India is currently trading at Rs. 8049.00, up by 338.15 points or 4.39% from its previous closing of Rs. 7710.85 on the BSE. The scrip opened at Rs. 8000.00 and has touched a high and low of Rs. 8117.25 and Rs. 7849.25 respectively. So far 2732 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 9370.35 on 23-Feb-2024 and a 52 week low of Rs. 5329.70 on 03-May-2023. Last one week high and low of the scrip st...
Sanofi India shines on entering into partnership with Cipla
Sanofi India shines on entering into partnership with Cipla
Source: Accord Fintech
2024-03-27 12:04:40 pm
Select healthcare stocks witness gains on the BSE Select healthcare stocks witnessed gains on the BSE during the afternoon deals. Ajanta Pharma, Abbott India and Cipla were among gainers in the healthcare index. Abbott India is currently trading at Rs. 27356.90, up by 351.90 points or 1.30% from its previous closing of Rs. 27005.00 on the BSE. Ajanta Pharma is currently trading at Rs. 2093.00, up by 5.40 points or 0.26% from its previous closing of Rs. 2087.60 on the BSE. Cipla is currently trading at Rs. 1467.95, up by 2.65 points ...
Select healthcare stocks witness gains on the BSE
Select healthcare stocks witness gains on the BSE
Source: Accord Fintech
2024-03-13 03:51:54 pm
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review, CEO David Ricks told Reuters on Wednesday. The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are making their own versions of such...
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
Source: Reuters
2024-02-28 05:09:26 pm
India pharma companies develop versions of Wegovy to get in on weight-loss windfall  Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. ...
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
Source: Reuters
2024-02-22 12:03:24 pm
Accumulate Cipla Ltd For Target Rs. 1,499 - Elara Capital gRevlimid bigger; others delayed Results ahead of estimates, driven primarily by gRevlimid Cipla (CIPLA IN) Q3 results were ahead of our revenue, EBITDA and PAT estimates by 6%, 18% and 40%, respectively. While it seems to have performed well across segments, a major part of the outperformance was driven by higher gRevlimid contribution in the US, in our view. gRevlimid contributed ~USD 60mn to the US business in Q3, as per our estimates...
Accumulate Cipla Ltd For Target Rs. 1,499 - Elara Capital
Accumulate Cipla Ltd For Target Rs. 1,499 - Elara Capital
Source: Elara Capital
2024-02-18 09:47:41 am
Cipla gains on tying up with CSIR-CDRI Cipla is currently trading at Rs. 1438.20, up by 15.35 points or 1.08% from its previous closing of Rs. 1422.85 on the BSE. The scrip opened at Rs. 1434.85 and has touched a high and low of Rs. 1444.05 and Rs. 1427.65 respectively. So far 20544 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1462.20 on 13-Feb-2024 and a 52 week low of Rs. 852.00 on 22-Mar-2023. Last one week high and low of the scrip stood at Rs...
Cipla gains on tying up with CSIR-CDRI
Cipla gains on tying up with CSIR-CDRI
Source: Accord Fintech
2024-02-16 11:31:29 am
Valentine Pick 2024 : Buy CIPLA @ 1450 & add Upto 1415 for the Target of 1600/ 1660 by Choice Broking CIPLA is currently trading at ?1450, moving within the range of 1420 to 1450 and showing signs of readiness for a breakout. The formation of new higher highs and higher lows suggests a potential upward movement, with projected targets at ?1600 and ?1660. Importantly, significant support is evident around ?1415. Moreover, CIPLA is trading above key Exponential Moving Averages (EMAs), including the 20-day, 50-day, 100-day, and 200-day EMAs, indicating a robust bullish momentum. The Relative ...
Valentine Pick 2024 : Buy CIPLA @ 1450 & add Upto 1415 for the Target of 1600/ 1660 by Choice Broking
Valentine Pick 2024 : Buy CIPLA @ 1450 & add Upto 1415 for the Target of 1600/ 1660 by Choice Broking
Source: Choice Broking
2024-02-13 04:52:52 pm
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets. Consolidated net profit for the company rose 27% to 7.90 billion rupees (about $95 million) for the three months ended Dec. 31, beating analysts' average estimate of 6.83 billion rupees, as per LSEG data. Separately, Zydus Lifesciences approved the buyback of shares worth six billion rupees via tender offer r...
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback
Source: Reuters
2024-02-09 02:38:55 pm
Cipla inches up as its arm completes acquisition of 100% equity stake in Actor Pharma Cipla is currently trading at Rs. 1442.15, up by 3.10 points or 0.22% from its previous closing of Rs. 1439.05 on the BSE. The scrip opened at Rs. 1445.05 and has touched a high and low of Rs. 1457.20 and Rs. 1440.65 respectively. So far 8220 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,457.20 on 08-Feb-2024 and a 52 week low of Rs. 852.00 on 22-Mar-2023. Last one week high and low of the scrip stood at Rs....
Cipla inches up as its arm completes acquisition of 100% equity stake in Actor Pharma
Cipla inches up as its arm completes acquisition of 100% equity stake in Actor Pharma
Source: Accord Fintech
2024-02-08 10:24:38 am
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand  India's J B Chemicals and Pharmaceuticals reported its sixth straight quarter of profit rise on Tuesday, led by strong demand in its domestic and international markets. The company's consolidated net profit was 1.34 billion rupees (nearly $16 million) for the quarter ended Dec. 31, compared with 1.06 billion rupees a year earlier. The Mumbai-based company's sales have benefitted from a series of acquisitions involving companies with portfolios of cardiovascular and oph...
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand
Source: Reuters
2024-02-06 05:14:44 pm
Cipla rises on acquiring additional stake in GoApptiv Cipla is currently trading at Rs. 1413.60, up by 22.15 points or 1.59% from its previous closing of Rs. 1391.45 on the BSE. The scrip opened at Rs. 1397.90 and has touched a high and low of Rs. 1418.55 and Rs. 1395.05 respectively. So far 1731 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1424.65 on 23-Jan-2024 and a 52 week low of Rs. 852.00 on 22-Mar-2023. Last one week high and low of the scrip stood at Rs....
Cipla rises on acquiring additional stake in GoApptiv
Cipla rises on acquiring additional stake in GoApptiv
Source: Accord Fintech
2024-02-05 09:40:54 am
Add Cipla Ltd For Target Rs.1,541 - Choice Broking * North America Business: In Q3FY24, North America recorded the revenue of INR 19,160mn (US$ 230mn, +18% YoY), driven by continuing momentum in key assets and robust demand in base business along with some year-end buying. In US, the price erosion was stable in the range of 4-6%. The management’s focus remains on commercial execution of existing portfolio and resolution of USFDA observations. The company is ready with one peptide asset and is waiting for the approval to launch (expec...
Add Cipla Ltd For Target Rs.1,541 - Choice Broking
Add Cipla Ltd For Target Rs.1,541 - Choice Broking
Source: Choice Broking
2024-01-31 12:24:54 pm
Buy Cipla Ltd Target Rs.1,540 - Motilal Oswal Financial Services Ltd Striving for sustainable growth beyond FY24 A robust ANDA pipeline to overcome price erosion and deliver growth * After exhibiting a moderate 7% YoY earnings growth in FY23, we expect Cipla to end FY24 on a strong note with a 26% YoY earnings growth. Cipla has executed efforts to improve its growth outlook beyond FY24. * On the India business front, in particular, Cipla is working to not only enhance its prescription base but also strengthen its trade generics and consumer healthcare...
Buy Cipla Ltd Target Rs.1,540 - Motilal Oswal Financial Services Ltd
Buy Cipla Ltd Target Rs.1,540 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-01-23 06:26:10 pm
India`s Cipla Q3 profit tops estimates on North America sales boost Indian generic drugmaker Cipla on Monday reported its third-quarter profit above analysts expectations, boosted by strong performances in North American and domestic markets. Consolidated net profit rose 32% to 10.56 billion Indian rupees ($127.1 million) in the quarter ended Dec. 31 from a year earlier, compared with average analysts' estimate of 10.43 billion rupees, according to LSEG data. Sales in North America grew 20% during the quarter, partially driven by strong demand for C...
India`s Cipla Q3 profit tops estimates on North America sales boost
India`s Cipla Q3 profit tops estimates on North America sales boost
Source: Reuters
2024-01-23 09:15:29 am
Stock of the day : Cipla Ltd For Target Rs. 1390 - Religare Broking Ltd Cipla Ltd Buy Cipla Ltd CMP 1322.95; Range 1320-1325 SL 1280; Target 1390   Please refer disclaimer at https://www.religareonline.com/disclaimer SEBI Registration number is INZ000174330
Stock of the day : Cipla Ltd For Target Rs. 1390 - Religare Broking Ltd
Stock of the day : Cipla Ltd For Target Rs. 1390 - Religare Broking Ltd
Source: Religare Broking Ltd
2024-01-19 10:10:42 am
For 2024, StoxBox suggests Cipla, Dr. Reddy`s.Torrent Pharma & Alkem Lab The US generics market and branded markets have seen significant growth, with moderate raw material costs and new medicines. Domestic pharmaceutical businesses are expected to grow in CY24 due to new product releases, volume growth, and increasing demand for generics and branded pharmaceuticals. Promising stocks Cipla & Dr. Reddy's US-focused pharma companies such as Sun Pharma, Lupin, and Dr. Reddy's are our preferred picks as they witnessed normalcy in demand, new launches...
For 2024, StoxBox suggests Cipla, Dr. Reddy`s.Torrent Pharma & Alkem Lab
For 2024, StoxBox suggests Cipla, Dr. Reddy`s.Torrent Pharma & Alkem Lab
Source: PR Agency
2024-01-11 12:09:40 pm
Stock of the day : CIPLA Ltd For Target Rs. 23 - Religare Broking CIPLA Ltd. * Pharma sector trading strong around life highs and CIPLA is trading insync. * It has rebounded higher finding support near its previous resistance zone while holding above its short term moving average. * Following price action and buoyancy in pharma space suggests prevailing trend to strengthen further. * We thus recommend creating fresh longs in the mentioned range. BUY 625 PE State Bank of India CMP 12.25; Range 11-33; SL 08; Target 78   ...
Stock of the day : CIPLA Ltd For Target Rs. 23 - Religare Broking
Stock of the day : CIPLA Ltd For Target Rs. 23 - Religare Broking
Source: Religare Broking Ltd
2024-01-10 10:33:42 am
Stock of the day : Cipla Ltd For Target Rs. 1315 - Religare Broking Cipla Ltd  * Pharma sector trading strong around life highs and CIPLA is trading insync. * It has rebounded higher finding support near its previous resistance zone while holding above its short term moving average. * Following price action and buoyancy in pharma space suggests price to witness breakout from the ongoing range. * We thus recommend creating fresh longs in the mentioned range. Buy Cipla Ltd CMP 1251.00; Range 1250-1254; SL 1220; Target 1315 &...
Stock of the day : Cipla Ltd For Target Rs. 1315 - Religare Broking
Stock of the day : Cipla Ltd For Target Rs. 1315 - Religare Broking
Source: Religare Broking Ltd
2024-01-02 10:45:34 am
India's Biocon misses Q2 profit view on higher expenses Indian biopharmaceutical company Biocon reported a smaller-than-expected quarterly profit on Friday hurt by higher expenses. The company's consolidated net profit rose to 1.26 billion rupees ($15.13 million) for the quarter ended Sept. 30 from 469 million rupees a year earlier. Analysts, however, had expected a profit of 1.77 billion rupees, according to LSEG data. Total expenses surged 59% to 33.58 billion rupees, the company said. Biocon also increased spending on research and ...
India's Biocon misses Q2 profit view on higher expenses
India's Biocon misses Q2 profit view on higher expenses
Source: Reuters
2023-11-12 08:53:38 am
Stock of the day : Cipla Ltd for Target Rs.1280 - Religare Broking Ltd CIPLA Ltd  * Seeing recovery in the pharma pack and Cipla is trading in line with trend. * Formed a base around the support zone of short term moving average i.e. 20 EMA. * Chart pattern combined with buoyancy in the pharma pack is pointing towards breakout. * We thus recommend creating fresh longs in the mentioned range BUY CIPLA Ltd CMP (?)1216.45; Range* 1215-1220; SL 1190; Target 1280   Please refer disclaimer at https://www.religareonline.com/...
Stock of the day : Cipla Ltd for Target Rs.1280 - Religare Broking Ltd
Stock of the day : Cipla Ltd for Target Rs.1280 - Religare Broking Ltd
Source: Religare Broking Ltd
2023-11-08 11:31:49 am
Cipla gains on getting nod to transfer generics business undertaking Cipla is currently trading at Rs. 1211.55, up by 7.50 points or 0.62% from its previous closing of Rs. 1204.05 on the BSE. The scrip opened at Rs. 1204.50 and has touched a high and low of Rs. 1211.95 and Rs. 1201.85 respectively. So far 5373 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023. Last one week high and low of the scrip stood at Rs. ...
Cipla gains on getting nod to transfer generics business undertaking
Cipla gains on getting nod to transfer generics business undertaking
Source: Accord Fintech
2023-11-07 11:53:34 am
Neutral Cipla Ltd For Target Rs.1,450 - Motilal Oswal Financial Services NA/DF drives improved profitability EBITDA margin guidance further raised to 23-24% for FY24 * CIPLA beat our earnings estimates in 2QFY24, led by a superior performance in the branded generics segment of domestic formulation (DF) and SAGA. The company sustained robust sales growth in North America (NA), led by market share gain and healthy demand for its base portfolio. * We raise our earnings estimates by 7%/4.4% for FY24/FY25, factoring in better growth prospects in DF, increased ...
Neutral Cipla Ltd For Target Rs.1,450 - Motilal Oswal Financial Services
Neutral Cipla Ltd For Target Rs.1,450 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
2023-11-03 12:54:04 pm
Cipla climbs on reporting 45% rise in Q2 consolidated net profit Cipla is currently trading at Rs. 1178.10, up by 27.95 points or 2.43% from its previous closing of Rs. 1150.15 on the BSE. The scrip opened at Rs. 1155.55 and has touched a high and low of Rs. 1196.85 and Rs. 1151.00 respectively. So far 45211 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023. Last one week high and low of the scrip stood at Rs...
Cipla climbs on reporting 45% rise in Q2 consolidated net profit
Cipla climbs on reporting 45% rise in Q2 consolidated net profit
Source: Accord Fintech
2023-10-27 02:55:24 pm
Nifty closed in the green on 5 occasions in month of November for last 10 yrs An analysis for the month of November indicated that the Nifty had closed in the green on five occasions with an average return of 1.2 per cent in the last 10 years, JM Financial Institutional Securities said in a report.The Nifty Mid-cap index, on the other hand, has shown a relatively stronger seasonality, closing in the green on eight occasions with an average return of 2.1 per cent, the report said.It has managed to outperform the Nifty on seven occasions with an average outperformance of...
Nifty closed in the green on 5 occasions in month of November for last 10 yrs
Nifty closed in the green on 5 occasions in month of November for last 10 yrs
Source: IANS
2023-10-26 01:52:06 pm
Kedar Upadhye appointed new CFO of Biocon Biologics Kedar Upadhye has been appointed as the new Chief Financial Officer (CFO) of Biocon Biologics while current CFO, M.B. Chinappa will take on a strategic finance role at Biocon Group. These leadership changes will be effective October 31, stated an official release on Thursday.M.B. Chinappa has served as CFO of Biocon Biologics since his appointment in January 2020 and has played an integral role in developing business strategy and enabling profitable growth. He has helped secure over $500 mill...
Kedar Upadhye appointed new CFO of Biocon Biologics
Kedar Upadhye appointed new CFO of Biocon Biologics
Source: IANS
2023-10-20 09:25:15 am
Cipla gains on launching drone-powered critical medicine delivery in Himachal Pradesh Cipla is currently trading at Rs. 1175.95, up by 12.15 points or 1.04% from its previous closing of Rs. 1163.80 on the BSE.The scrip opened at Rs. 1172.45 and has touched a high and low of Rs. 1188.40 and Rs. 1171.65 respectively. So far 34612 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023.Last one week high and low of the scrip stood at Rs. 1240.00 and Rs. 11...
Cipla gains on launching drone-powered critical medicine delivery in Himachal Pradesh
Cipla gains on launching drone-powered critical medicine delivery in Himachal Pradesh
Source: Accord Fintech
2023-09-27 02:13:15 pm
Stock of the day : Cipla Ltd For Target Rs. 30 - Religare Broking Ltd Cipla Ltd.* Pharma pack is witnessing profit booking and CIPLA is trading insync. * It has registered a breakdown from sideways consolidation and closed below its short term average. * Stock has witnessed a breakdown from Squeeze Bollinger bands indicates profit booking to extend further. * We thus recommend initiating fresh shorts through the Put option.Buy Cipla Ltd. CMP 11.45; Range 11-12; SL 3; Target 30Please refer disclaimer at https://www.religareonline.com/disclaime...
Stock of the day : Cipla Ltd For Target Rs. 30 - Religare Broking Ltd
Stock of the day : Cipla Ltd For Target Rs. 30 - Religare Broking Ltd
Source: Religare Broking Ltd
2023-09-22 10:42:09am
India`s Torrent Pharma in talks with CVC, Bain Capital for Cipla bid- sources India's Torrent Pharmaceuticals is in talks with private equity funds CVC Capital Partners and Bain Capital to raise up to $1.5 billion to bid for India's Cipla, according to three sources with direct knowledge of the matter.Torrent and Blackstone are among those interested to acquire a stake in Cipla, India's third-biggest drugmaker by sales, in what could be the largest pharma deal in India ever.Cipla's founding family is keen to sell their 33.4% holding entirely, sources say, and any bid w...
India`s Torrent Pharma in talks with CVC, Bain Capital for Cipla bid- sources
India`s Torrent Pharma in talks with CVC, Bain Capital for Cipla bid- sources
Source: Reuters
2023-09-19 10:34:09am
India`s Torrent Pharma in talks with CVC, Bain Capital for Cipla bid India's Torrent Pharmaceuticals is in talks with private equity funds CVC Capital Partners and Bain Capital to raise up to $1.5 billion to bid for India's Cipla, according to three sources with direct knowledge of the matter.Torrent and Blackstone are among those interested to acquire a stake in Cipla, India's third-biggest drugmaker by sales, in what could be the largest pharma deal in India ever.Cipla's founding family is keen to sell their 33.4% holding entirely, sources say, and any bid w...
India`s Torrent Pharma in talks with CVC, Bain Capital for Cipla bid
India`s Torrent Pharma in talks with CVC, Bain Capital for Cipla bid
Source: Reuters
2023-09-18 03:55:27pm
Buy Cipla Ltd For Target Rs.1,420 - Motilal Oswal Financial Services Expanding portfolio by adding Pepitides/Injectable/Inhalers* During FY13-FY23, CIPLA?s US sales clocked a 21.6% CAGR to reach USD733m in FY23 (26% of sales). This was the highest growth rate among our coverage companies. Despite higher price erosion in FY23 at industry level, CIPLA recorded a sales growth of 8% YoY backed by g-Revlimid launch and market share gains in lanreotide, Albuterol and Arformoterol. * While CIPLA is focusing on its efforts towards resolving regulatory issues at ...
Buy Cipla Ltd For Target Rs.1,420 - Motilal Oswal Financial Services
Buy Cipla Ltd For Target Rs.1,420 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
2023-09-18 02:26:53pm